Kidney Medullary Carcinoma clinical trials at UC Health
1 research study open to new patients
Study looking at targeted chemotherapy and immunotherapy in treating patients with advanced/metastatic genitourinary tumors
“Targeted chemotherapy and immunotherapy medicine with or without additional immunotherapy medicine to treat bladder/urothelial cancer”
open to eligible people ages 18 years and up
This phase I trial studies the side effects and best doses of cabozantinib-s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread to other places in the body. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib-s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.
at UC Davis